There is a sea change in IoT and biomems technology at stake here that goes way beyond vision technology. The microarchitecture and the power source to drive this tech that EPGL has been developing will end up in every part of the body to either enhance or correct physiological defects and will allow machines to enter the "smart age", just like phones already have. Even if the news is simply a "happy new year" statement from the foks at EPGL, this is no time to get rid of our shares and miss the boat. If this is the extent of the announcement, many will no doubt complain once again that real news is not forthcoming and that we're being strung along. However, the simple fact of the matter is that with newly patented advanced technology the market has not seen before, timetables sometimes can be suspended due to the need to develope other supporting software and hardware. It's often a matter of logistics. It doesn't stop the progress though. It only delays it. We see it all the time with companies like Apple and Intel where some new feature that will impact their product is announced and then delayed. But it does eventually come.
The word here is "hang on." Actually that's two words, but we need to hang on to our shares so that we can hang on to the IoT biomems rocket ship about to depart.
Enjoy the ride!
